58068-85-2

Basic information

• Product Name: DMABA NHS ester
• Synonyms: DMABA NHS ester;1-[[4-(DiMethylaMino)benzoyl]oxy]-;4-(DiMethylaMino)benzoic Acid 2,5-Dioxo-1-pyrrolidinyl Ester;N-Succinimidyl 4-(dimethylamino)benzoate
• CAS NO: 58068-85-2
• Molecular Formula: C₁₃H₁₄N₂O₄
• Molecular Weight: 262.26126
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 58068-85-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Dichloromethane (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly)
• Stability: Moisture Sensitive, unstable in protic solvent
• BRN: 1479401
• CAS DataBase Reference: DMABA NHS ester(CAS DataBase Reference)
• NIST Chemistry Reference: DMABA NHS ester(58068-85-2)
• EPA Substance Registry System: DMABA NHS ester(58068-85-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 58068-85-2(Hazardous Substances Data)

Usage

Uses

Used in Biochemical Research:
DMABA NHS ester is used as a reagent for labeling and detecting primary amine groups in proteins and lipids. Its application is particularly relevant in the study of PE (phosphatidylethanolamine) lipids, where it helps in identifying and quantifying changes in lipid abundance before and after radical oxidation.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, DMABA NHS ester is employed as a key component in the development of drug conjugates. Its ability to react with primary amine groups allows for the creation of targeted drug delivery systems, enhancing the specificity and efficacy of therapeutic agents.
Used in Diagnostic Applications:
DMABA NHS ester is also utilized in the development of diagnostic tools, such as immunoassays and biosensors. Its reactivity with primary amine groups enables the detection and quantification of specific biomarkers, contributing to the early diagnosis and monitoring of various diseases.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 619-84-1 p-N,N-dimethylaminobenzoic acid 
• 10287-53-3 ethyl p-dimethyaminolbenzoate 

Downstream Products

• 1175002-12-6 C₅₀H₈₇N₂O₉P 
• 792936-62-0 4-(N,N-dimethylamino)-N'-(6-hydroxyhexyl)benzamide 

Relevant articles and documents

Permanently Positively Charged Stable Isotope Labeling Agents and Its Application in the Accurate Quantitation of Alkylphenols Migrated from Plastics to Edible Oils

A new permanently positively charged stable isotope labeling (SIL) agent pair, 4-(((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl)-N,N,N-Trimethylbenzenaminium iodide(DPTBA) and its deuterated counterpart d3-DPTBA, was designed and synthesized. The SIL agents wer

Preparation method of amboryl ester type sugar marker with permanent charges and application

The invention provides a preparation method of an amboryl ester type sugar marker with permanent charges and belongs to the technical field of organic synthesis and bioinformation. The amboryl ester type sugar marker with permanent charges is prepared from benzocaine through a series of synthesis, has the advantages that the reaction conditions (45 DEG C for 40 min) are mild, detection sensitivity can be improved and deviation yield is high, the deviation yield reaches 98%, the product can be detected with HPLC (high-performance liquid chromatography and MS (mass spectrometry) (ESI-MS and MALDI-ToF-MS), and the sensitivity is high.

IMAGING PROBES, FORMULATIONS, AND USES THEREOF

Described herein are single and dual modality bisphosphonate conjugated imaging probes. Also described herein are methods of synthesizing and using the single and dual modality bisphosphonate conjugated imaging probes.

Chemical remodeling of cell-surface sialic acids through a palladium-triggered bioorthogonal elimination reaction

We herein report a chemical decaging strategy for the in situ generation of neuramic acid (Neu), a unique type of sialic acid, on live cells by the use of a palladium-mediated bioorthogonal elimination reaction. Palladium nanoparticles (Pd NPs) were found to be a highly efficient and biocompatible depropargylation catalyst for the direct conversion of metabolically incorporated N-(propargyloxycarbonyl)neuramic acid (Neu5Proc) into Neu on cell-surface glycans. This conversion chemically mimics the enzymatic de-N-acetylation of N-acetylneuramic acid (Neu5Ac), a proposed mechanism for the natural occurrence of Neu on cell-surface glycans. The bioorthogonal elimination was also exploited for the manipulation of cell-surface charge by unmasking the free amine at C5 to neutralize the negatively charged carboxyl group at C1 of sialic acids.

Development and characterization of improved β-lactone-based anti-virulence drugs targeting ClpP

Here, we report the synthesis and in depth characterization of a second generation β-lactone derived virulence inhibitors. Based on initial results that emphasized the intriguing possibility to disarm bacteria in their virulence the present study develops

Structure-based design and synthesis of the first weak non-phosphate inhibitors for IspF, an enzyme in the non-mevalonate pathway of isoprenoid biosynthesis

In this paper, we describe the structure-based design, synthesis, and biological evaluation of cytosine derivatives and analogues that inhibit IspF, an enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. This pathway is responsible for the biosynthesis of the C5 precursors to isoprenoids, isopentenyl diphosphate (IPP, 1) and dimethylallyl diphosphate (DMAPP, 2; Scheme 1). The non-mevalonate pathway is the sole source for 1 and 2 in the protozoan Plasmodium parasites. Since mammals exclusively utilize the alternative mevalonate pathway, the enzymes of the non-mevalonate pathway have been identified as attractive new drug targets in the fight against malaria. Based on computer modeling (cf. Figs. 2 and 3), new cytosine derivatives and analogues (Fig. 1) were selected as potential drug-like inhibitors of IspF protein, and synthesized (Schemes 2-5). Determination of the enzyme activity by 13C-NMR spectroscopy in the presence of the new ligands showed inhibitory activities for some of the prepared cytosine and pyridine-2,5-diamine derivatives in the upper micromolar range (IC50 values; Table). The data suggest that it is possible to inhibit IspF protein without binding to the polar diphosphate binding site and the side chain of Asp56′, which interacts with the ribose moiety of the substrate and substrate analogues. Furthermore, a new spacious sub-pocket was discovered which accommodates aromatic spacers between cytosine derivatives or analogues (binding to 'Pocket III') and rings that occupy the flexible hydrophobic region of 'Pocket II'. The proposed binding mode remains to be further validated by X-ray crystallography.